Compare Bristol-Myers Squibb Co (BMY) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Gartner Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.3 (market cap $116.30B), while Gartner Inc trades at $134.65 (market cap $8.90B). The key difference: Bristol-Myers Squibb Co is far larger — about 13.1× Gartner Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| BMY | IT | |
|---|---|---|
Market Cap | $116.30B | $8.90B |
Sector | Health | Technology |
52-Week High | $62.37 | $363.58 |
52-Week Low | $42.60 | $125.68 |
Enterprise Value | $152.24B | $10.49B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Gartner (IT) trades at $141.31, up 6.06% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729 million. Recent news highlights its leadership in AI platforms, but an ongoing legal investigation poses a near-term risk.
Outlook remains positive with a consensus price target of $157.60, suggesting 11.5% upside. Key opportunities include sustained demand for IT research and consulting, while risks involve heightened competition and the February 2025 legal probe. Institutional sentiment is mixed with 27.8% buy ratings amid cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
